A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(23 sites)

United States

The University of Alabama at Birmingham, Birmingham, Alabama

University of Arizona, Tucson, Arizona

Stanford University, Palo Alto, California

UCSD, San Diego, California

National Jewish Health, Denver, Colorado